These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

553 related items for PubMed ID: 17353550

  • 1. Bortezomib is active in patients with untreated or relapsed Waldenstrom's macroglobulinemia: a phase II study of the National Cancer Institute of Canada Clinical Trials Group.
    Chen CI, Kouroukis CT, White D, Voralia M, Stadtmauer E, Stewart AK, Wright JJ, Powers J, Walsh W, Eisenhauer E, National Cancer Institute of Canada Clinical Trials Group.
    J Clin Oncol; 2007 Apr 20; 25(12):1570-5. PubMed ID: 17353550
    [Abstract] [Full Text] [Related]

  • 2. Treatment of relapsed or refractory Waldenström's macroglobulinemia with bortezomib.
    Dimopoulos MA, Anagnostopoulos A, Kyrtsonis MC, Castritis E, Bitsaktsis A, Pangalis GA.
    Haematologica; 2005 Dec 20; 90(12):1655-8. PubMed ID: 16330439
    [Abstract] [Full Text] [Related]

  • 3. Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphoma.
    Goy A, Younes A, McLaughlin P, Pro B, Romaguera JE, Hagemeister F, Fayad L, Dang NH, Samaniego F, Wang M, Broglio K, Samuels B, Gilles F, Sarris AH, Hart S, Trehu E, Schenkein D, Cabanillas F, Rodriguez AM.
    J Clin Oncol; 2005 Feb 01; 23(4):667-75. PubMed ID: 15613697
    [Abstract] [Full Text] [Related]

  • 4. Phase I/II trial assessing bortezomib and melphalan combination therapy for the treatment of patients with relapsed or refractory multiple myeloma.
    Berenson JR, Yang HH, Sadler K, Jarutirasarn SG, Vescio RA, Mapes R, Purner M, Lee SP, Wilson J, Morrison B, Adams J, Schenkein D, Swift R.
    J Clin Oncol; 2006 Feb 20; 24(6):937-44. PubMed ID: 16418495
    [Abstract] [Full Text] [Related]

  • 5. Bortezomib in recurrent and/or refractory multiple myeloma. Initial clinical experience in patients with impared renal function.
    Jagannath S, Barlogie B, Berenson JR, Singhal S, Alexanian R, Srkalovic G, Orlowski RZ, Richardson PG, Anderson J, Nix D, Esseltine DL, Anderson KC, SUMMIT/CREST Investigators.
    Cancer; 2005 Mar 15; 103(6):1195-200. PubMed ID: 15690325
    [Abstract] [Full Text] [Related]

  • 6. Multicenter clinical trial of bortezomib in relapsed/refractory Waldenstrom's macroglobulinemia: results of WMCTG Trial 03-248.
    Treon SP, Hunter ZR, Matous J, Joyce RM, Mannion B, Advani R, Cook D, Songer J, Hill J, Kaden BR, Sharon D, Steiss R, Leleu X, Branagan AR, Badros A.
    Clin Cancer Res; 2007 Jun 01; 13(11):3320-5. PubMed ID: 17545538
    [Abstract] [Full Text] [Related]

  • 7. A phase II study of bortezomib in the treatment of metastatic malignant melanoma.
    Markovic SN, Geyer SM, Dawkins F, Sharfman W, Albertini M, Maples W, Fracasso PM, Fitch T, Lorusso P, Adjei AA, Erlichman C.
    Cancer; 2005 Jun 15; 103(12):2584-9. PubMed ID: 15887220
    [Abstract] [Full Text] [Related]

  • 8. Phase II study of single-agent bortezomib for the treatment of patients with fludarabine-refractory B-cell chronic lymphocytic leukemia.
    Faderl S, Rai K, Gribben J, Byrd JC, Flinn IW, O'Brien S, Sheng S, Esseltine DL, Keating MJ.
    Cancer; 2006 Sep 01; 107(5):916-24. PubMed ID: 16832816
    [Abstract] [Full Text] [Related]

  • 9. Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma.
    Fisher RI, Bernstein SH, Kahl BS, Djulbegovic B, Robertson MJ, de Vos S, Epner E, Krishnan A, Leonard JP, Lonial S, Stadtmauer EA, O'Connor OA, Shi H, Boral AL, Goy A.
    J Clin Oncol; 2006 Oct 20; 24(30):4867-74. PubMed ID: 17001068
    [Abstract] [Full Text] [Related]

  • 10. Safety of prolonged therapy with bortezomib in relapsed or refractory multiple myeloma.
    Berenson JR, Jagannath S, Barlogie B, Siegel DT, Alexanian R, Richardson PG, Irwin D, Alsina M, Rajkumar SV, Srkalovic G, Singhal S, Limentani S, Niesvizky R, Esseltine DL, Trehu E, Schenkein DP, Anderson K.
    Cancer; 2005 Nov 15; 104(10):2141-8. PubMed ID: 16206291
    [Abstract] [Full Text] [Related]

  • 11. Phase II trial of PS-341 in patients with renal cell cancer: a University of Chicago phase II consortium study.
    Davis NB, Taber DA, Ansari RH, Ryan CW, George C, Vokes EE, Vogelzang NJ, Stadler WM.
    J Clin Oncol; 2004 Jan 01; 22(1):115-9. PubMed ID: 14701773
    [Abstract] [Full Text] [Related]

  • 12. Phase I study of the proteasome inhibitor bortezomib in pediatric patients with refractory solid tumors: a Children's Oncology Group study (ADVL0015).
    Blaney SM, Bernstein M, Neville K, Ginsberg J, Kitchen B, Horton T, Berg SL, Krailo M, Adamson PC.
    J Clin Oncol; 2004 Dec 01; 22(23):4804-9. PubMed ID: 15570082
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Bortezomib, bendamustine, and rituximab in patients with relapsed or refractory follicular lymphoma: the phase II VERTICAL study.
    Fowler N, Kahl BS, Lee P, Matous JV, Cashen AF, Jacobs SA, Letzer J, Amin B, Williams ME, Smith S, Saleh A, Rosen P, Shi H, Parasuraman S, Cheson BD.
    J Clin Oncol; 2011 Sep 01; 29(25):3389-95. PubMed ID: 21810687
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Bortezomib, low-dose intravenous melphalan, and dexamethasone for patients with relapsed multiple myeloma.
    Popat R, Oakervee H, Williams C, Cook M, Craddock C, Basu S, Singer C, Harding S, Foot N, Hallam S, Odeh L, Joel S, Cavenagh J.
    Br J Haematol; 2009 Mar 01; 144(6):887-94. PubMed ID: 19183191
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Phase II trial of weekly bortezomib in combination with rituximab in untreated patients with Waldenström Macroglobulinemia.
    Ghobrial IM, Xie W, Padmanabhan S, Badros A, Rourke M, Leduc R, Chuma S, Kunsman J, Warren D, Poon T, Harris B, Sam A, Anderson KC, Richardson PG, Treon SP, Weller E, Matous J.
    Am J Hematol; 2010 Sep 01; 85(9):670-4. PubMed ID: 20652865
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 28.